Tysabri approved as Crohn's treatment
The FDA today approved Elan and Biogen IDEC's supplemental biologics license application for Tysabri to treat Crohn's disease, a chronic and progressive disease marked by inflammation of the bowel.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.